JEFFERSON CITY, Mo. (AP) — Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer.

The proposed settlement comes as the U.S. Supreme Court is preparing to hear arguments in April on Bayer’s assertion that the U.S. Environmental Protection Agency’s approval of Roundup without a cancer warning should invalidate claims filed in state courts. That case would not be affected by the proposed settlement.

But the settlement would eliminate some of the risk from an eventual Supreme Court ruling. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer’s favor. And Bayer would be protected from potentially larger costs if the high court rules against it.

Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup’s key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in U.S. agricultural markets.

The proposed settlement was filed in St. Louis Circuit Court in Missouri, home to Bayer’s North America crop science division and the state where many of the lawsuits have been brought. The settlement still needs the court’s approval.

About 200,000 Roundup-related claims have been made against Bayer. That includes more than 125,000 plaintiffs who sued since 2015, according to the settlement documents. Few cases have gone to jurors, with 13 verdicts for Bayer and 11 for plaintiffs, including a $2.1 billion award by a Georgia jury last year. Others already have been resolved through separate settlements, including two recent ones that would take care of about 77,000 claims, the court documents said.